205 related articles for article (PubMed ID: 24867687)
21. Efficacy of DHMEQ, a NF-κB inhibitor, in islet transplantation: I. HMGB1 suppression by DHMEQ prevents early islet graft damage.
Kuraya D; Watanabe M; Koshizuka Y; Ogura M; Yoshida T; Asahi Y; Kamachi H; Nakamura T; Harashima H; Ozaki M; Umezawa K; Matsushita M; Yamashita K; Todo S
Transplantation; 2013 Sep; 96(5):445-53. PubMed ID: 23900151
[TBL] [Abstract][Full Text] [Related]
22. Dehydroxymethylepoxyquinomicin, a novel nuclear Factor-kappaB inhibitor, enhances antitumor activity of taxanes in anaplastic thyroid cancer cells.
Meng Z; Mitsutake N; Nakashima M; Starenki D; Matsuse M; Takakura S; Namba H; Saenko V; Umezawa K; Ohtsuru A; Yamashita S
Endocrinology; 2008 Nov; 149(11):5357-65. PubMed ID: 18653704
[TBL] [Abstract][Full Text] [Related]
23. Induction of histidine decarboxylase in macrophages inhibited by the novel NF-kappaB inhibitor (-)-DHMEQ.
Suzuki E; Ninomiya Y; Umezawa K
Biochem Biophys Res Commun; 2009 Feb; 379(2):379-83. PubMed ID: 19103154
[TBL] [Abstract][Full Text] [Related]
24. Targeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in murine epithelial ovarian cancer.
Khan AN; Kolomeyevskaya N; Singel KL; Grimm MJ; Moysich KB; Daudi S; Grzankowski KS; Lele S; Ylagan L; Webster GA; Abrams SI; Odunsi K; Segal BH
Oncotarget; 2015 May; 6(13):11310-26. PubMed ID: 25888637
[TBL] [Abstract][Full Text] [Related]
25. Antitumor effects of dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, in human liver cancer cells are mediated through a reactive oxygen species-dependent mechanism.
Lampiasi N; Azzolina A; D'Alessandro N; Umezawa K; McCubrey JA; Montalto G; Cervello M
Mol Pharmacol; 2009 Aug; 76(2):290-300. PubMed ID: 19461054
[TBL] [Abstract][Full Text] [Related]
26. Control of allograft rejection by applying a novel nuclear factor-kappaB inhibitor, dehydroxymethylepoxyquinomicin.
Ueki S; Yamashita K; Aoyagi T; Haga S; Suzuki T; Itoh T; Taniguchi M; Shimamura T; Furukawa H; Ozaki M; Umezawa K; Todo S
Transplantation; 2006 Dec; 82(12):1720-7. PubMed ID: 17198266
[TBL] [Abstract][Full Text] [Related]
27. Amelioration of experimental autoimmune uveoretinitis with nuclear factor-{kappa}B Inhibitor dehydroxy methyl epoxyquinomicin in mice.
Iwata D; Kitaichi N; Miyazaki A; Iwabuchi K; Yoshida K; Namba K; Ozaki M; Ohno S; Umezawa K; Yamashita K; Todo S; Ishida S; Onoé K
Invest Ophthalmol Vis Sci; 2010 Apr; 51(4):2077-84. PubMed ID: 19907030
[TBL] [Abstract][Full Text] [Related]
28. Potent cytotoxic effect of a novel nuclear factor-kappaB inhibitor dehydroxymethylepoxyquinomicin on human bladder cancer cells producing various cytokines.
Kodaira K; Kikuchi E; Kosugi M; Horiguchi Y; Matsumoto K; Kanai K; Suzuki E; Miyajima A; Nakagawa K; Tachibana M; Umezawa K; Oya M
Urology; 2010 Apr; 75(4):805-12. PubMed ID: 20156648
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of canonical NF-κB nuclear localization by (-)-DHMEQ via impairment of DNA binding.
Horie K; Ma J; Umezawa K
Oncol Res; 2015; 22(2):105-15. PubMed ID: 25706397
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
[TBL] [Abstract][Full Text] [Related]
31. IL-12 regulates B7-H1 expression in ovarian cancer-associated macrophages by effects on NF-κB signalling.
Xiong HY; Ma TT; Wu BT; Lin Y; Tu ZG
Asian Pac J Cancer Prev; 2014; 15(14):5767-72. PubMed ID: 25081699
[TBL] [Abstract][Full Text] [Related]
32. Dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, induces apoptosis in multiple myeloma cells in an IkappaBalpha-independent manner.
Tatetsu H; Okuno Y; Nakamura M; Matsuno F; Sonoki T; Taniguchi I; Uneda S; Umezawa K; Mitsuya H; Hata H
Mol Cancer Ther; 2005 Jul; 4(7):1114-20. PubMed ID: 16020669
[TBL] [Abstract][Full Text] [Related]
33. Sub-optimal primary surgery leads to unfavorable immunological changes in ovarian cancer patients.
Nowak M; Głowacka E; Lewkowicz P; Banasik M; Szyłło K; Zimna K; Bednarska K; Klink M
Immunobiology; 2018 Jan; 223(1):1-7. PubMed ID: 29017822
[TBL] [Abstract][Full Text] [Related]
34. Identification of the RelA domain responsible for action of a new NF-kappaB inhibitor DHMEQ.
Watanabe M; Nakashima M; Togano T; Higashihara M; Watanabe T; Umezawa K; Horie R
Biochem Biophys Res Commun; 2008 Nov; 376(2):310-4. PubMed ID: 18782563
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of macrophage activation and phagocytosis by a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin.
Suzuki E; Umezawa K
Biomed Pharmacother; 2006 Nov; 60(9):578-86. PubMed ID: 16978829
[TBL] [Abstract][Full Text] [Related]
36. CD40 activation in epithelial ovarian carcinoma cells modulates growth, apoptosis, and cytokine secretion.
Gallagher NJ; Eliopoulos AG; Agathangelo A; Oates J; Crocker J; Young LS
Mol Pathol; 2002 Apr; 55(2):110-20. PubMed ID: 11950960
[TBL] [Abstract][Full Text] [Related]
37. Galectin-3 regulates metastatic capabilities and chemotherapy sensitivity in epithelial ovarian carcinoma via NF-κB pathway.
Lu H; Liu Y; Wang D; Wang L; Zhou H; Xu G; Xie L; Wu M; Lin Z; Yu Y; Li G
Tumour Biol; 2016 Aug; 37(8):11469-77. PubMed ID: 27012551
[TBL] [Abstract][Full Text] [Related]
38. Immunomodulatory effect of nuclear factor-κB inhibition by dehydroxymethylepoxyquinomicin in combination with donor-specific blood transfusion.
Goto R; Yamashita K; Aoyagi T; Ueki S; Uno M; Oura T; Kobayashi N; Igarashi R; Shibasaki S; Wakayama K; Hirokata G; Shibata T; Zaitsu M; Umezawa K; Ozaki M; Todo S
Transplantation; 2012 Apr; 93(8):777-86. PubMed ID: 22357176
[TBL] [Abstract][Full Text] [Related]
39. A novel NF-kappaB inhibitor DHMEQ selectively targets constitutive NF-kappaB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo.
Watanabe M; Dewan MZ; Okamura T; Sasaki M; Itoh K; Higashihara M; Mizoguchi H; Honda M; Sata T; Watanabe T; Yamamoto N; Umezawa K; Horie R
Int J Cancer; 2005 Mar; 114(1):32-8. PubMed ID: 15523684
[TBL] [Abstract][Full Text] [Related]
40. Dual targeting of transformed and untransformed HTLV-1-infected T cells by DHMEQ, a potent and selective inhibitor of NF-kappaB, as a strategy for chemoprevention and therapy of adult T-cell leukemia.
Watanabe M; Ohsugi T; Shoda M; Ishida T; Aizawa S; Maruyama-Nagai M; Utsunomiya A; Koga S; Yamada Y; Kamihira S; Okayama A; Kikuchi H; Uozumi K; Yamaguchi K; Higashihara M; Umezawa K; Watanabe T; Horie R
Blood; 2005 Oct; 106(7):2462-71. PubMed ID: 15956280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
